Pfizer - 41 Year Stock Price History | PFE
Historical daily share price chart and data for Pfizer since 1984 adjusted for splits and dividends. The latest closing stock price for Pfizer as of April 15, 2025 is 22.44.
- The all-time high Pfizer stock closing price was 52.61 on December 16, 2021.
- The Pfizer 52-week high stock price is 31.54, which is 40.6% above the current share price.
- The Pfizer 52-week low stock price is 20.91, which is 6.8% below the current share price.
- The average Pfizer stock price for the last 52 weeks is 27.37.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Pfizer Historical Annual Stock Price Data |
| Year |
Average Stock Price |
Year Open |
Year High |
Year Low |
Year Close |
Annual % Change |
| 2025 |
25.5705 |
26.1772 |
26.9100 |
21.5900 |
22.4400 |
-14.02% |
| 2024 |
26.7054 |
27.5617 |
30.4072 |
23.7701 |
26.0985 |
-2.22% |
| 2023 |
33.3972 |
45.4589 |
45.4589 |
24.2243 |
26.6903 |
-41.26% |
| 2022 |
43.5215 |
48.6587 |
48.6930 |
36.7105 |
45.4412 |
-10.41% |
| 2021 |
35.6669 |
30.4269 |
52.6098 |
27.9837 |
50.7201 |
66.69% |
| 2020 |
28.3407 |
29.4432 |
35.1798 |
21.6510 |
30.4269 |
3.24% |
| 2019 |
29.5194 |
31.3684 |
32.7728 |
25.5102 |
29.4733 |
-6.90% |
| 2018 |
27.9773 |
25.5163 |
33.5298 |
23.7671 |
31.6586 |
24.83% |
| 2017 |
23.4504 |
22.2315 |
26.0484 |
20.9852 |
25.3622 |
15.91% |
| 2016 |
21.7411 |
20.7386 |
24.6810 |
18.7248 |
21.8812 |
4.43% |
| 2015 |
21.5524 |
19.6780 |
23.0958 |
19.5712 |
20.9528 |
7.09% |
| 2014 |
18.7294 |
18.4802 |
20.1553 |
17.2484 |
19.5649 |
5.28% |
| 2013 |
17.3302 |
15.2111 |
19.5359 |
15.1759 |
18.5833 |
26.22% |
| 2012 |
13.3935 |
12.4123 |
15.1482 |
11.9591 |
14.7234 |
20.43% |
| 2011 |
10.8212 |
9.5848 |
12.3332 |
9.3184 |
12.2258 |
28.79% |
| 2010 |
8.9127 |
9.8472 |
10.4038 |
7.5034 |
9.4927 |
0.32% |
| 2009 |
8.0314 |
9.0209 |
9.8056 |
5.8812 |
9.4622 |
8.21% |
| 2008 |
9.2236 |
10.6124 |
11.1544 |
7.1348 |
8.7444 |
-16.95% |
| 2007 |
11.4346 |
11.6333 |
12.5153 |
10.3299 |
10.5290 |
-8.13% |
| 2006 |
11.1716 |
10.1390 |
12.4869 |
9.7387 |
11.4607 |
15.27% |
| 2005 |
10.7273 |
10.9428 |
12.1296 |
8.7831 |
9.9429 |
-10.62% |
| 2004 |
13.4849 |
14.4067 |
15.7441 |
10.0492 |
11.1249 |
-22.30% |
| 2003 |
12.8168 |
12.5404 |
14.5254 |
11.4144 |
14.3176 |
17.76% |
| 2002 |
13.7502 |
15.6386 |
16.5204 |
10.2270 |
12.1585 |
-22.16% |
| 2001 |
16.2548 |
17.8933 |
17.8933 |
13.8714 |
15.6190 |
-12.47% |
| 2000 |
16.0518 |
12.2580 |
18.9043 |
11.7590 |
17.8448 |
43.05% |
| 1999 |
14.7569 |
15.7002 |
19.1186 |
12.1377 |
12.4743 |
-21.50% |
| 1998 |
12.9358 |
9.5493 |
16.0339 |
9.3285 |
15.8909 |
68.92% |
| 1997 |
7.0616 |
5.1010 |
9.8174 |
5.1010 |
9.4074 |
81.92% |
| 1996 |
4.5320 |
3.8133 |
5.6384 |
3.7214 |
5.1711 |
33.99% |
| 1995 |
2.8654 |
2.2123 |
4.0584 |
2.1723 |
3.8593 |
71.62% |
| 1994 |
1.8738 |
1.9217 |
2.2887 |
1.5271 |
2.2487 |
15.32% |
| 1993 |
1.7913 |
1.9920 |
2.0838 |
1.4962 |
1.9500 |
-2.28% |
| 1992 |
2.0434 |
2.2665 |
2.3137 |
1.8034 |
1.9954 |
-11.96% |
| 1991 |
1.5858 |
1.0569 |
2.3137 |
0.9844 |
2.2665 |
112.78% |
| 1990 |
0.8886 |
0.9043 |
1.0751 |
0.7195 |
1.0652 |
20.33% |
| 1989 |
0.7881 |
0.7098 |
0.9521 |
0.6719 |
0.8852 |
24.17% |
| 1988 |
0.6491 |
0.5750 |
0.7237 |
0.5750 |
0.7129 |
29.29% |
| 1987 |
0.7650 |
0.7127 |
0.8895 |
0.4922 |
0.5514 |
-21.36% |
| 1986 |
0.6844 |
0.5585 |
0.8255 |
0.5250 |
0.7012 |
24.00% |
| 1985 |
0.5094 |
0.4368 |
0.6227 |
0.4164 |
0.5655 |
23.71% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$151.025B |
$63.627B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
